News Update: MSD confirms $3bn takeover of EyeBio MSD has confirmed a $3 billion takeover deal for ophthalmology biotech EyeBio and its drug candidate for diabetic macular oedema (DME) and neovascular age-related macular
News After rebuffing Biogen, Sage pairs off with Supernus Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face